Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-08-05 18:17Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has experienced significant stock price fluctuations, with a cumulative decline exceeding 12% over three consecutive trading days, leading to abnormal trading conditions [4]. Group 1: Stock Trading Abnormalities - The company's stock price fell by more than 12% cumulatively over three trading days (August 1, August 4, and August 5, 2025), indicating abnormal trading conditions [4]. - The company has received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties due to inflated revenue and profit figures in its annual reports from 2020 to 2023 [10]. Group 2: Financial Reporting Issues - The company's 2024 annual financial report received a disclaimer of opinion from the auditing firm, which may lead to delisting risks under the Shanghai Stock Exchange rules [2][3]. - There are issues related to non-operating fund occupation by related parties of the controlling shareholder, with a reported balance of 169.26 million yuan as of the end of 2023 [11]. Group 3: Operational Status - The company has confirmed that, aside from disclosed matters, there have been no significant changes in its daily operations or external environment [5]. - No undisclosed major events, such as asset restructuring or significant business cooperation, have been identified [6]. Group 4: Risks and Future Considerations - The company is under a delisting risk warning due to the CSRC's findings, which could lead to mandatory delisting if further penalties are imposed [10]. - The company’s subsidiary may lose exclusive rights to sell a product, which could significantly impact revenue and profits in the second half of the year [12].